<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Stocks on FinanClub</title>
    <link>https://finan.club/tags/stocks/</link>
    <description>Recent content in Stocks on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 06 Feb 2024 09:04:33 +0000</lastBuildDate><atom:link href="https://finan.club/tags/stocks/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>GM</title>
      <link>https://finan.club/us/gm/</link>
      <pubDate>Tue, 06 Feb 2024 09:04:33 +0000</pubDate>
      
      <guid>https://finan.club/us/gm/</guid>
      <description>score:45
Chances: The mean of analysts&amp;rsquo; price targets for General Motors Company (GM) points to a 26% upside in the stock. General Motors Company (GM) has been one of the stocks most watched by Zacks.com users lately, indicating strong market interest. If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, General Motors Company (GM) could be a great choice.</description>
    </item>
    
    <item>
      <title>APP</title>
      <link>https://finan.club/us/app/</link>
      <pubDate>Wed, 24 Jan 2024 09:04:31 +0000</pubDate>
      
      <guid>https://finan.club/us/app/</guid>
      <description>score:-63
Chances: AppLovin has been hot, and the run higher might have some momentum. AppLovin (APP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company&amp;rsquo;s earnings prospects. Risks: It&amp;rsquo;s always important to assess the risk involved in investing in a company, especially in the volatile tech sector.</description>
    </item>
    
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Tue, 19 Dec 2023 09:06:54 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-135
Chances: AstraZeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. The additional supply of RSV shot for infants by AstraZeneca and Sanofi indicates a positive outlook for meeting winter demand.</description>
    </item>
    
  </channel>
</rss>
